77361-32-1

Usage

Uses

Used in Pharmaceutical Industry:
N-1-BOC-2-(1',3'-DIHYDRO-1',3'-DIOXO-2'H-ISOINDOL-2'-YL) ETHYLAMINE is used as an intermediate in the preparation of various pharmaceuticals for its ability to be incorporated into the molecular structures of these compounds, enhancing their therapeutic properties.
Used in Antibacterial Agents:
In the field of antibacterial agents, N-1-BOC-2-(1',3'-DIHYDRO-1',3'-DIOXO-2'H-ISOINDOL-2'-YL) ETHYLAMINE is used as a key component in the synthesis of various compounds that exhibit potent antibacterial activity, contributing to the development of new and effective treatments against bacterial infections.
Used in Drug Metabolites:
N-1-BOC-2-(1',3'-DIHYDRO-1',3'-DIOXO-2'H-ISOINDOL-2'-YL) ETHYLAMINE is also utilized in the study and production of drug metabolites, which are the byproducts of drug metabolism in the body. Its unique structure allows for the investigation of metabolic pathways and the development of drugs with improved pharmacokinetics and reduced side effects.

Upstream product

• 85-44-9 phthalic anhydride 
• 57260-73-8 N-BOC-1,2-diaminoethane 

Downstream Products

• 121495-40-7 tert-butyl (2-(1,3-dioxoisoindolin-2-yl)ethyl)(methyl)carbamate 
• 886767-93-7 tert-butyl 3-(4-(trifluoromethyl)phenyl)piperazine-1-carboxylate 
• 1557288-14-8 tert-butyl 3-(2-chloro-4-fluorophenyl)piperazine-1-carboxylate 
• 886768-17-8 tert-butyl 3-(4-methoxyphenyl)piperazine-1-carboxylate 
• 886769-95-5 tert-butyl 3-(benzo[d][1,3]dioxol-5-yl)piperazine-1-carboxylate 
• 183742-29-2 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 886779-61-9 tert-butyl 3-(tert-butyl)piperazine-1-carboxylate 
• 886779-85-7 tert-butyl 3-cyclopropylpiperazine-1-carboxylate 

Relevant academic research and scientific papers

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHOIPHILIC COMPOUNDS CONTAINING HYDRIPHOBIC RADICALS

A composition in the form of an injectable solution includes: amylin, an amylin receptor agonist or an amylin analog; at least one ionic species; and an amphiphilic compound having a hydrophilic skeleton HB, substituted by at least one hydrophobic radical -Hy according to formula (I). A composition further is characterised in that it also has prandial insulin. In one embodiment, the composition also has GLP-1, GLP-1 analogs, and GLP-1 receptor agonists, commonly called GLP-1 RA.

Thermally induced substrate release via intramolecular cyclizations of Amino esters and Amino carbonates

The relative cleavage of an alcohol from a panel of amino esters and amino carbonates via intramolecular cyclization was examined as a mechanism for substrate release. Thermal stability at 37 °C was observed only for the seven-membered ring progenitors. Applicability of the approach was illustrated by δ-lactam formation within a poly(dimethylsiloxane) microchannel for release of a captured fluorescent probe.

Development of unsymmetrical dyads as potent noncarbohydrate-based inhibitors against human β-N-acetyl-D-hexosaminidase

Human β-N-acetyl-D-hexosaminidase has gained much attention due to its roles in several pathological processes and been considered as potential targets for disease therapy. A novel and efficient skeleton, which was an unsymmetrical dyad containing naphthalimide and methoxyphenyl moieties with an alkylamine spacer linkage as a noncarbohydrate-based inhibitor, was synthesized, and the activities were valuated against human β-N-acetyl-D- hexosaminidase. The most potent inhibitor exhibits high inhibitory activity with Ki values of 0.63 μM. The straightforward synthetic manners of these unsymmetrical dyads and understanding of the binding model could be advantageous for further structure optimization and development of new therapeutic agents for Hex-related diseases.

MELANOCORTIN RECEPTOR AGONISTS

The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.